SCHEMBL3194387

SCHEMBL3194387

COCOc1ccc(C(=O)O)c(OCc2ccc(Cl)cc2Cl)c1C

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 2/20 0.60
FABP4 P15090 2/20 0.60
FABP5 Q01469 2/20 0.60
MRGPRX4 Q96LA9 8/20 0.54
PTGER1 P34995 4/20 0.48
NR4A2 P43354 2/20 0.47
HDAC8 Q9BY41 1/20 0.45
NR4A1 P22736 1/20 0.45
NR4A3 Q92570 1/20 0.45
SLC26A4 O43511 1/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 1/20 0.42
BLM P54132 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221047 0.90 FABP3 (0.47) FABP3FABP4FABP5MRGPRX4PTGER1
SCHEMBL4633654 0.90 FABP3 (0.58) FABP3FABP4FABP5MRGPRX4PTGER1
SCHEMBL3210788 0.86 FABP3 (0.44) FABP3FABP4FABP5MRGPRX4PTGER1
SCHEMBL3198974 0.82 PTGER3 (0.46) FABP3FABP4FABP5MRGPRX4PTGER1
SCHEMBL3198991 0.82 PTGER3 (0.46) FABP3FABP4FABP5MRGPRX4PTGER1
SCHEMBL3215715 0.81 ALDH1A1 (0.49) FABP3FABP4FABP5MRGPRX4PTGER1
SCHEMBL4602246 0.76 FABP3 (0.44) FABP3FABP4FABP5MRGPRX4PTGER1
SCHEMBL5839536 0.75 FABP4 (1.00) FABP3FABP4FABP5MRGPRX4PTGER1
SCHEMBL3194736 0.73 PTGER3 (0.45) FABP3FABP4FABP5MRGPRX4PTGER1
SCHEMBL3194755 0.73 PTGER3 (0.45) FABP3FABP4FABP5MRGPRX4PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 FABP3 5/4885FABP4 1/4885FABP5 49/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 FABP3 4/4885FABP4 1/4885FABP5 45/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 FABP3 5/4885FABP4 1/4885FABP5 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.